Closing the Innovation Gap: Why Drug Discovery Breakthroughs Are Failing to Reach Patients
Why do so many drug discovery breakthroughs fail to reach patients? Trisha Pillay speaks with Christian Nkanga to find out.
Insights
In-depth articles and expert analysis from pharmaceutical leaders, exploring advances in life sciences, drug development and the trends shaping healthcare innovation.
Image
The Future for Decentralised Clinical Trials
Image
Reimagine AI-driven Drug Discovery with Pharmaceutical Superintelligence
Image
First Quarter 2026 State of Digital Health Funding
Image
Maximise Pharma Innovation With Quality-by-Design
Image
Digital Twins in Clinical Trials: Simulating Success Before Enrolment
Image
Phenotypic Drug Discovery: Beyond the Target
Image
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Explore All Insights
Browse our complete library of expert articles and analysis. Explore content across science, policy and life sciences innovation.
Reimagine AI-driven Drug Discovery with Pharmaceutical Superintelligence
Explore how AI-driven drug discovery is evolving through Pharmaceutical Superintelligence and what your organisation can do to keep up.
First Quarter 2026 State of Digital Health Funding
Digital health funding hit $7.4B in Q1 2026, the highest since Q2 2022. The CB Insights State of Digital Health report reveals where capital is concentrating and why it matters for pharma leaders.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
Phenotypic Drug Discovery: Beyond the Target
Phenotypic drug discovery is reshaping how pharma finds first-in-class drugs. This analysis covers the methods, AI integration, and strategic decisions R&D leaders face in 2026.
The Looming Threat of Geopolitical Risk in Clinical Supply Chains
Geopolitical risk is reshaping how clinical supply chains are managed, demanding resilience and foresight. Learn why building supply chain resilience is the key for clinical trial success.
Cell Therapy for Solid Tumours: Current Challenges and New Advances
Cell therapy for solid tumours faces unique biological barriers. This analysis unpacks the engineering strategies pharma leaders must understand for R&D success in 2026.
Why Precision Alone Isn't Enough in Oncology Drug Discovery
Precision alone isn’t enough in oncology drug discovery. See why execution, biomarkers, and trial design determine scalable success in precision medicine.
Drug Discovery and Pharmacoinformatics in 2026
Pharmacoinformatics is redefining drug discovery strategy. This analysis covers the AI platforms, molecular design tools, and regulatory frameworks shaping R&D pipelines in 2026.
Seven Ways AI Is Solving Pharmaceutical Supply Chain Problems
AI is tackling the pharmaceutical supply chain's most persistent problems, from demand forecasting to counterfeit detection. See the top 7 ways AI is improving supply chain resiliency.
What 13 Years of Data Shows About Drug Innovation in Psychiatry
From 2012 through 2024, the FDA only approved 22 drugs for the treatment of psychiatric conditions. Pharma R&D teams must rethink development strategies to unstall drug innovation in psychiatry
What Pharma R&D Tech Investment Committees Actually Fund
What do pharma R&D tech investment committees really fund? Learn how workflow fit, enterprise pull, and strategic relevance drive adoption.
Modern Drug Discovery Challenges Demand a New Pharma Paradigm
Explore the biggest drug discovery challenges facing pharma today, from translational gaps to AI integration, and why a new pharma paradigm is needed.